Monoclonal antibody specifically binding to human SIRP alpha and application of monoclonal antibody in preparation of antitumor drugs
By developing human SIRPα monoclonal antibodies with high affinity and specificity, the damage problem of existing drugs targeting SIRPα-CD47 pathway to normal cells has been solved, and a safer and more effective tumor treatment effect has been achieved.
Patent Information
- Application Number
- CN202310650852.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-02
- Publication Date
- 2024-12-03
AI Technical Summary
Existing drugs targeting SIRPα-CD47 pathways may damage normal cells due to their wide distribution of CD47, resulting in side effects such as anemia and leukopenia, and lack of high affinity and specific monoclonal antibodies.
Developed a monoclonal antibody that specifically binds human SIRPα, containing optimized heavy and light chain variable region amino acid sequences, with high affinity and functionality, capable of specifically blocking the binding of human SIRPα and human CD47, and in Cross-reactivity is shown in nonhuman primates.
This monoclonal antibody can specifically bind to human SIRPα with high affinity, block SIRPα-CD47 signaling pathway, reduce side effects, improve therapeutic benefits, and show performance better than existing antibodies in preclinical studies.
Smart Images

Figure CN119060181A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a monoclonal antibody specifically binding to human SIRPα and use thereof in preparing anti-tumor drugs. Background Art
[0002] Signal regulatory protein α (SIRPα), also known as PTPNS1, SHPS1, CD172A or P84, is a transmembrane protein expressed on the surface of myeloid hematopoietic cells (e.g., macrophages, dendritic cells) and neurons. SIRPα consists of an extracellular domain containing three IgG-like domains and a cytoplasmic domain containing immunoreceptor tyrosine inhibitory motifs (ITIMs). When phosphorylated, ITIMs recruit inhibitory molecules, especially protein tyrosine phosphatases SHP-1 and SHP-2 containing Src homology 2 domains (Matozaki T. et al. (2009). "Functions and molecular mechanisms of the CD47-SIRPαsignalling pathway". Trends Cell Biol. 19(2): 72–80).
[0003] CD47, also known as integrin-associated protein (IAP), is a ligand of SIRPα. It is expressed on all normal cells, but is often overexpressed on cancer cells. Its molecular structure includes an extracellular variable domain at the N-terminus, five hydrophobic transmembrane helical structures, and a very short intracellular signal sequence at the C-terminus. Under physiological conditions, SIRPα-CD47 plays an important role in maintaining body tolerance and assisting immune response as an immune checkpoint. However, in tumor tissues, SIRPα on the surface of phagocytes such as macrophages and dendritic cells binds to CD47 on the surface of tumor cells, triggering the coupling of SIRPα with SHP-1 and SHP-2 phosphatases, inhibiting downstream myosin IIA, inhibiting the phagocytosis of macrophages, and achieving immune escape. Blocking the SIRPα-CD47 signaling pathway will reduce the recruitment of SHP-1 and SHP-2, activate the prophagocyte receptor to trigger phagocytosis, restore the uptake of tumor cells by dendritic cells, facilitate antigen presentation, and promote cytokine secretion.
[0004] Increasing evidence suggests that blocking the SIRPα-CD47 pathway is a promising approach to treating cancer. This has led to the development of a variety of SIRPα-CD47 blockers, and these drugs have shown good tumor therapeutic effects in vitro and preclinical studies. However, most drugs targeting the SIRPα-CD47 pathway target the CD47 molecule, such as recombinant SIRPα-Fc fusion protein or IgG1 anti-CD47 antibody. However, due to the wide distribution of CD47, it may damage hematopoietic and non-hematopoietic cells that normally express CD47, causing anemia, thrombocytopenia and / or leukopenia (Veillette A. et al. (2018). "SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy". Trends Immunol. 39(3): 173-184). In contrast, SIRPα has the characteristics of limited histological distribution and abnormal expression in specific solid tumors (e.g., renal cell carcinoma and melanoma), which enables it to inhibit CD47 / SIRPα signals in tumors at relatively low doses.
[0005] To date, there are increasing studies on monotherapy or combination therapy of anti-SIRPα antibodies. Among them, CC95251 (Celgene) is a monoclonal antibody that specifically targets SIRPα and can block the SIRPα-CD47 interaction. This antibody can convert myeloid-derived suppressor cells and tumor-associated suppressor cells into non-suppressor cells, thereby leading to the reactivation of the immune system and inhibiting tumor growth. The monoclonal antibody KWAR23 can bind to SIRPα at the epitope of the SIRPα-CD47 interface, and in in vitro studies, KWAR23 alone or in combination with Cetuximab can enhance macrophage-mediated phagocytosis of colorectal adenocarcinoma cells in a concentration-dependent manner.
[0006] Although there are already a variety of antibodies targeting SIRPα in the clinical stage, there is still a need to further develop monoclonal antibodies with higher SIRPα specificity and affinity. Summary of the invention
[0007] In order to overcome the above-mentioned defects, the purpose of the present invention is to provide a monoclonal antibody that specifically binds to human SIRPα and its use in the preparation of anti-tumor drugs, wherein the antibody has high affinity and functionality, which is superior to the existing anti-human SIRPα monoclonal antibodies.
[0008] The technical solution provided by the present invention is as follows:
[0009] A monoclonal antibody that specifically binds to human SIRPα, the antibody comprising a heavy chain variable region and a light chain variable region;
[0010] The heavy chain variable region comprises CDR-H1, CDR-H2 and CDR-H3, and the light chain variable region comprises CDR-L1, CDR-L2 and CDR-L3;
[0011] The amino acid sequence of the CDR-H1 is shown in SEQ ID NO: 2;
[0012] The amino acid sequence of the CDR-H2 is shown in SEQ ID NO: 4;
[0013] The amino acid sequence of the CDR-H3 is shown in SEQ ID NO: 6;
[0014] The amino acid sequence of the CDR-L1 is shown in SEQ ID NO: 12;
[0015] The amino acid sequence of the CDR-L2 is shown in SEQ ID NO: 14;
[0016] The amino acid sequence of the CDR-L3 is shown in SEQ ID NO: 16.
[0017] Preferably, the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 8; and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 18.
[0018] Preferably, the heavy chain amino acid sequence is shown as SEQ ID NO: 10; and the light chain amino acid sequence is shown as SEQ ID NO: 20.
[0019] Preferably, both the heavy chain and the light chain further comprise a constant region, which is a constant region of mouse IgG, preferably a constant region of IgG1.
[0020] The present invention further provides a nucleotide molecule, which encodes the monoclonal antibody that specifically binds to human SIRPα;
[0021] Preferably, the sequence of the nucleotide molecule is selected from SEQ ID NO: 7 and SEQ ID NO: 17;
[0022] The sequence SEQ ID NO: 7 encodes the heavy chain variable region of the monoclonal antibody;
[0023] The sequence SEQ ID NO: 17 encodes the light chain variable region of the monoclonal antibody.
[0024] The present invention further provides an expression vector, which contains the nucleotide molecule.
[0025] The present invention further provides a host cell, wherein the host cell contains the expression vector.
[0026] Preferably, the host cell is a eukaryotic cell, preferably a mammalian cell.
[0027] The present invention further provides a method for preparing a monoclonal antibody that specifically binds to human SIRPα, the preparation method comprising the following steps:
[0028] Step 1: preparing an expression vector containing a nucleotide molecule that expresses the monoclonal antibody that specifically binds to human SIRPα;
[0029] Step 2: transfecting eukaryotic host cells with the expression vector of step 1;
[0030] Step 3: culturing the eukaryotic host cells transfected in step 2;
[0031] Step 4: separation and purification to obtain the monoclonal antibody.
[0032] The present invention also relates to an antibody immunoconjugate, a bispecific molecule, a chimeric antigen receptor or a pharmaceutical composition comprising the aforementioned monoclonal antibody that specifically binds to human SIRPα.
[0033] Furthermore, the pharmaceutical composition comprises a therapeutically effective amount of the monoclonal antibody that specifically binds to human SIRPα, and one or more pharmaceutically acceptable carriers, diluents or excipients.
[0034] The present invention further provides use of the monoclonal antibody specifically binding to human SIRPα in the preparation of anti-tumor drugs.
[0035] Preferably, the tumor is non-small cell lung cancer, breast cancer, ovarian cancer, renal cell carcinoma, colorectal cancer or pancreatic cancer.
[0036] The present invention has the following advantages: the monoclonal antibody of the present invention can specifically bind to human SIRPα with high affinity, and has cross-reactivity with cynomolgus monkey SIRPα, and can also specifically block the binding between human SIRPα and human CD47, and has a novel sequence.
[0037] In addition, due to the continuous improvement of the safety evaluation standards for new drugs, the research and development of all new drugs must obtain reliable conclusions on non-human primates before entering clinical research. In the preclinical research of biological products, the use rate of cynomolgus monkeys is relatively high, and they are an important biological model in biological research. Therefore, monoclonal antibodies with cross-reactivity to cynomolgus monkey antigens are more beneficial for subsequent clinical research. BRIEF DESCRIPTION OF THE DRAWINGS
[0038] Figure 1 The affinity of mouse antibody A1C8E4H1 was determined by BIACORE surface plasmon resonance method;
[0039] Figure 2 The ability of antibody A1C8E4H1 to bind to human SIRPα protein was determined by capture ELISA;
[0040] Figure 3 Indirect ELISA was used to determine the binding ability of antibody A1C8E4H1 to human SIRPα protein;
[0041] Figure 4 Indirect ELISA was used to determine the cross-reactivity of antibody A1C8E4H1 to human SIRPβ protein;
[0042] Figure 5 Blocking ELISA for reference antibody;
[0043] Figure 6 Flow cytometry was used to evaluate the ability of antibody A1C8E4H1 to block the binding of human SIRPα protein to human CD47 protein on the cell membrane surface. DETAILED DESCRIPTION
[0044] the term
[0045] "Binding to SIRPα" or "binding to SIRPα" means being able to interact with human SIRPα. "Specific binding" means being able to bind to human SIRPα protein (and possibly SIRPα protein from one or more non-human species) but not substantially binding to non-SIRPα proteins.
[0046] “Antigen binding site” refers to one or more fragments of an antibody that have the ability to specifically bind to an antigen (eg, SIRPα protein).
[0047] "Monoclonal antibody" refers to a preparation of antibody molecules having a single amino acid composition, exhibiting a single binding specificity and affinity for a particular epitope. Monoclonal antibodies or antigen-binding fragments thereof can be prepared, for example, by hybridoma technology, recombinant DNA technology, phage display technology, synthetic technology such as CDR grafting technology, or a combination of such or other techniques known in the art.
[0048] "Affinity" refers to the strength of the sum of all non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, herein, "binding affinity" refers to the intrinsic binding affinity reflecting a 1:1 interaction between an antibody and an antigen. Affinity can be measured by common methods known in the art, including those described in the prior art and herein.
[0049] The term "competition" when used in the context of antigen binding proteins (e.g., neutralizing antigen binding proteins or neutralizing antibodies) competing for the same epitope means competition between antigen binding proteins, which is determined by the following assay: in the assay, the antigen binding protein to be detected (e.g., an antibody or an immunologically functional fragment thereof) prevents or inhibits (e.g., reduces) the specific binding of a reference antigen binding protein (e.g., a ligand or a reference antibody) to a common antigen (e.g., SIRPα or a fragment thereof). Numerous types of competitive binding assays can be used to determine whether one antigen binding protein competes with another. Competitive inhibition is measured by measuring the amount of a marker bound to a solid surface or cell in the presence of the antigen binding protein being tested. Typically, the antigen binding protein being tested is present in excess. Antigen binding proteins identified by competitive assays (competing antigen binding proteins) include: antigen binding proteins that bind to the same epitope as the reference antigen binding protein; and antigen binding proteins that bind to adjacent epitopes that are sufficiently close to the binding epitope of the reference antigen binding protein, and the two epitopes sterically hinder each other from binding.
[0050] Methods for producing and purifying antibodies and antigen-binding fragments are well known and disclosed in the prior art, such as the Cold Spring Harbor Guide to Antibody Experimental Technology. For example, mice can be immunized with human SIRPα or its fragments, and the resulting antibodies can be renatured, purified, and amino acid sequenced using conventional methods. Antigen-binding fragments can also be prepared using conventional methods.
[0051] "Treatment" means administering an oral or topical therapeutic agent, such as a composition comprising a SIRPα antibody or an antigen-binding fragment thereof, to a patient who has one or more symptoms of a disease. Typically, the therapeutic agent is administered in an amount effective to alleviate one or more symptoms of the disease in the treated patient or population, either by inducing regression of such symptoms or inhibiting the development of such symptoms to any clinically measurable extent. The amount of therapeutic agent effective to alleviate any specific disease symptom (also referred to as a "therapeutically effective amount") may vary according to a variety of factors, such as the patient's disease state, age, and weight, and the ability of the drug to produce the desired therapeutic effect on the patient. Whether the symptoms of the disease have been alleviated can be evaluated by any clinical test method commonly used by physicians or other health care professionals to evaluate the severity or progression of the symptoms.
[0052] An "effective amount" includes an amount sufficient to improve or prevent the symptoms or symptoms of a medical condition. An effective amount also means an amount sufficient to allow or facilitate diagnosis. The effective amount for a particular patient or veterinary subject may vary depending on factors such as the condition to be treated, the patient's overall health, the method, route and dosage of administration, and the severity of side effects. An effective amount can be the maximum dose or dosage regimen that avoids significant side effects or toxic effects.
[0053] "Pharmaceutical composition" refers to a mixture containing one or more SIRPα antibodies or antigen-binding fragments thereof described herein and other pharmaceutical components, such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of the pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredient, and thus exert biological activity.
[0054] The present invention is further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples that do not specify specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer. Reagents that do not specify specific sources are conventional reagents purchased from the market.
[0055] Example 1 Obtaining mouse monoclonal antibodies specific to SIRPα by fusion hybridoma technology
[0056] 1.1 Animal immunization
[0057] Mice were immunized according to the common method in the literature (E Harlow, D. Lane, Antibody: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1998). The immunogen was a recombinant human SIRPα protein (amino acid Met 1-Arg 370) containing a human IgG1 Fc tag at the C-terminus, human SIRPα-Fc (produced by the company, the plasmid used was CD172-ECD-Fc; the vector was pCP; the inserted amino acid sequence was
[0058] MEPAGPAPGRLGPLLCLLLAASCAWSGVAGEEELQVIQPDKSVLVAAGETATLRCTATSLIPVGPIQW
[0059] FRGAGPGRELIYNQKEGHFPRVTTVSDLTKRNNMDFSIRIGNITPADAGTYYCVKFRKGSPDDVEFK
[0060] SGAGTELSVRAKPSAPVVSGPAARATPQHTVSFTCESHGFSPRDITLKWFKNGNELSDFQTNVDPVG
[0061] ESVSYSIHSTAKVVLTREDVHSQVICEVAHVTLQGDPLRGTANLSETIRVPPTLEVTQQPVRAENQVN
[0062] VTCQVRKFYPQRLQLTWLENGNVSRTETASTVTENKDGTYNWMSWLLVNVSAHRDDVKLTCQVEHDGQPAVSKSHDLKVSAHPKEQGSNTAAENTGSNER, SEQ ID NO: 23). Recombinant human SIRPα protein with his tag, human SIRPα-his (produced by the company, the plasmid used is SRPA-ECD-His; the vector is pCMV-C-His; the amino acid sequence is inserted between EcoR I and XbaI
[0063] MEPAGPAPGRLGPLLCLLLAASCAWSGVAGEEELQVIQPDKSVLVAAGETATLRCTATSLIPVGPIQW
[0064] FRGAGPGRELIYNQKEGHFPRVTTVSDLTKRNNMDFSIRIGNITPADAGTYYCVKFRKGSPDDVEFK
[0065] SGAGTELSVRAKPSAPVVSGPAARATPQHTVSFTCESHGFSPRDITLKWFKNGNELSDFQTNVDPVG
[0066] ESVSYSIHSTAKVVLTREDVHSQVICEVAHVTLQGDPLRGTANLSETIRVPPTLEVTQQPVRAENQVN
[0067] VTCQVRKFYPQRLQLTWLENGNVSRTETASTVTENKDGTYNWMSWLLVNVSAHRDDVKLTCQVEHDGQPAVSKSHDLKVSAHPKEQGSNTAAENTGSNER, SEQ ID NO: 23) was used as the detection antigen for determining serum titer and hybridoma screening. Briefly, an appropriate amount of Freund's adjuvant was taken into a 1.5ml EP tube and mixed with an oscillator. Human SIRPα-Fc antigen protein solution was prepared with PBS. The adjuvant and protein antigen solution were mixed according to the required amount, and the antigen was fully emulsified by pushing the syringe to form a stable oil-in-water solution, and then injected subcutaneously into mice. According to the results of serum titer determination, 2 to 3 booster immunizations were performed after the first immunization to achieve a good immune effect. The animals with good titers were given a final booster immunization by intraperitoneal injection, followed by cell fusion.
[0068] 1.2 Hybridoma fusion and screening
[0069] Before cell fusion, mouse myeloma cells (SP2 / 0-Ag14, ATCC#CRL-1581) were cultured in the logarithmic growth phase. The immune mice were sacrificed and the spleen was removed in a sterile environment. The spleen B cells and SP2 / 0 myeloma cells were fused using PEG chemistry according to the method in the literature (E Harlow, D. Lane, Antibody: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1998); Kohler G, and Milstein C, "Continuous cultures of fused cell secreting antibody of predefined specificity," Nature, 256: 495-497 (1975)).
[0070] The fused cells were plated on a 96-well cell culture plate. Surviving hybridoma cells were observed to grow under a microscope after 7 to 10 days. Two weeks after the cells were plated, the culture supernatant of each well was collected and hybridoma screening was performed using the capture ELISA method with human SIRPα-Fc protein antigen. Briefly described as follows: the ELISA plate was coated with 60 μl of PBS solution containing 1 μg / ml affinity-purified F(ab')2 fragment-specific goat anti-mouse IgG (Jackson Immunoresearch Laboratories, Inc., Cat#115-005-072) and incubated at 4°C overnight. The plate was then washed once with a PBS solution containing 0.05% v / v Tween-20 (i.e., PBST), and 200 μl / well of PBST solution containing 5% w / v skim milk powder was added, and the plate was blocked at 37°C for 2 hours. The plate was washed again, 60 μl / well of hybridoma supernatant was added, incubated at 37°C for 40 minutes, and then washed 4 times. Add 100 μl / well of biotin-labeled human SIRPα-Fc protein solution (1:5000 diluted in PBST containing 2.5% w / v skim milk powder), incubate at 37°C for 40 minutes, wash the plate 4 times, and pat dry. Then add 100 μl / well of horseradish peroxidase-labeled streptavidin (Jackson ImmunoResearch Laboratories, Inc., Cat#016-030-084) diluted 1:5000 in PBST solution containing 5% w / v skim milk powder, incubate at 37°C for 40 minutes, wash the plate 4 times, and pat dry. Add 100 μl / well of TMB (InnoReagents, Cat#TMB-S-002) color substrate, color develop at room temperature for 5 to 15 minutes, and then stop with 1M sulfuric acid solution, and measure the absorbance of each well at 450 nm. The hybridoma well cells with positive ELISA binding were selected, transferred to a 24-well plate, and continued to be cultured. A second round of screening was performed by ELISA method to screen out hybridomas that specifically recognize SIRPα antigen and can block CD47 / SIRPα binding, subcloned by limiting dilution method, and then purified. Briefly, the protein A agarose column was washed with 5-10 column volumes of PBS buffer. The cell supernatant of the hybridoma monoclonal antibody passed through the column, and then the column was washed with PBS buffer until the protein absorbance reached the baseline. The column was eluted with elution buffer (0.1M glycine-HCl, pH 2.7) and immediately collected in a 1.5ml tube containing neutral buffer (1MTris-HCl, pH 9.0). The fractions containing immunoglobulins were mixed and dialyzed in PBS at 4°C overnight. Subsequently, the functional activity of the purified monoclonal antibody was characterized in vitro as described below.
[0071] Example 2 Determination of the affinity of mouse anti-SIRPα monoclonal antibody using BIACORE surface plasmon resonance technology
[0072] The affinity kinetics of the mouse anti-SIRPα monoclonal antibody (mAb) produced by the hybridoma clones in Example 1 were characterized using the Biacore T200 system (GE healthcare, Pittsburgh, PA, USA).
[0073] The experimental process is as follows:
[0074] 1) Balance: dilute 10× buffer (HBS-EP) to 1× with ultrapure water, insert the left injection tube Tube A into the running 1× buffer bottle, and insert the right injection tube into fresh ultrapure water. Open Biacore T200 ControlSoftware 2.0, load the CM5 chip coupled with goat anti-mouse IgG protein, run the "Prime" program twice, and after the run is completed, the instrument automatically switches to Standby mode to balance the chip and buffer overnight;
[0075] 2) Capture quantity optimization: Mouse anti-SIRPα antibody or reference antibody (i.e., KWAR23 antibody, produced by the company, with heavy chain and light chain amino acid sequences of SEQ ID NO: 21 and 22, respectively) was flowed onto the chip at a concentration of 66.7 nM, with a flow rate of 10 μL / min;
[0076] 3) Affinity determination: In HBS-EP +200 nM, 100 nM, 50 nM, 25 nM, 12.5 nM, 6.25 nM human SIRPα-his or cynomolgus monkey SIRPα-his (produced by the company, the plasmid used is SRPA-ECD-His; the vector is pCMV-C-His; in EcoR I and Xba The amino acid sequence inserted between I is MEPAGPAPGRLGPLLCLLLTASCAWSGVLGEEELQVIQPEKSVSVAAGDSATLNCTVSSLIPVGPIQWFRGAGPGRELIYNLKEGHFPRVTAVSDPTKRNNMDFSIRISNITPADAGTYYCVKFRKGSPDVELKSGAGTELSVRAKPSAPVVSGPAVRATAEHTVSFTCESHGFSPRDITL KWFKNGNELSDVQTNVDPAGKSVSYSIRSTARVLLTRRDVHSQVICEVAHVTLQGDPLRGTANLSEAIRVPPFLEVTQQSMRADNQVNVTCQVTKFYPQRLQLTWLENGNVSRTEMASALPENKDGTYNWTSWLLVNVSAHRDDVKLTCQVEHDGQPAVNKSFSVKVSAHPKEQGSNTAAENTGTNER, SEQ ID NO: 24) Antigen solution. Edit the affinity determination program, set the capture flow rate to 10 μl / min, set the capture time, capture channel, protein injection flow rate to 30 μl / min, binding time to 120 s, dissociation time to 600 s, select a suitable sample slot, place the analyte in the sample slot according to the position set in the program, and run the program;
[0077] 4) The binding rate constant K of mouse antibody A1C8E4H1 to human SIRPα-his antigen or cynomolgus monkey SIRPα-his antigen was calculated using Biacore T200 Evaluation Software 2.0. a (1 / Ms), dissociation rate constant K d (1 / s), affinity constant K D (M), the results are shown in Table 1 and Figure 1 .
[0078] Table 1 Biacore evaluation of affinity of mouse anti-SIRPα monoclonal antibodies
[0079]
[0080] Binding K of the monoclonal antibody A1C8E4H1 of the present invention to human SIRPα DThe value is similar to that of the reference antibody, and the binding K D The value was at the level of 1.0E-07, indicating that it had high affinity for human SIRPα and cross-reactivity with cynomolgus monkey SIRPα.
[0081] Example 3 Determination of in vitro binding activity of anti-SIRPα monoclonal antibodies
[0082] 3.1 Determination of antibody binding capacity based on capture ELSIA
[0083] Affinity-purified F(ab')2 fragment-specific goat anti-mouse IgG (Jackson ImmunoResearch Laboratories, Inc., Cat#115-005-072) or affinity-purified F(ab')2 fragment-specific goat anti-human IgG (Jackson ImmunoResearch Laboratories, Inc., Cat#109-005-097) was prepared with 1xPBS to a final concentration of 2 μg / ml, and 100 μl / well was added to a 96-well ELISA plate and coated at 37°C for 2 hours. After coating, the plate was washed once with 1xPBST (PBS+0.05% v / v Tween-20), and 200 μl / well of PBST solution containing 5% w / v skim milk powder was added thereto, and the plate was blocked at 37°C for 2 hours. The plate was washed again, and 100 μl / well of gradient diluted antibody solution or control (initial concentration was 66.7 nM, 5-fold gradient dilution in PBST containing 2.5% w / v skim milk) was added to the plate, incubated at 37°C for 40 minutes, and the plate was washed again 4 times. 100 μl / well of biotin-labeled human SIRPα-Fc protein solution (83 ng / mL in PBST solution containing 2.5% skim milk powder) was added to the plate, incubated again at 37°C for 40 minutes, and then washed 4 times. Horseradish peroxidase-labeled streptavidin (1:10000 diluted in PBST buffer, Jackson ImmunoResearch Laboratories, Inc., Cat#016-030-084) was added at 100 μl / well and incubated at 37°C for 40 minutes. After the final wash, 100 μl / well of ELISA color substrate TMB (InnoReagents, Cat#TMB-S-002) was added and color was developed at room temperature for 5 to 15 minutes. Then, 1M sulfuric acid solution was used to terminate the color development and the absorbance of each well at 450-630 nm was measured. The data were analyzed using GraphPad Prism software to obtain EC 50 The specific results are as follows Figure 2 shown.
[0084] As can be seen from the figure, the monoclonal antibody A1C8E4H1 of the present invention can recognize human SIRPα antigen, and its binding activity is comparable to that of the reference antibody.
[0085] 3.2 Indirect ELISA to determine the binding ability of antibodies to human SIRPα
[0086] Human SIRPα-Fc antigen was prepared with carbonate / bicarbonate buffer (pH 9.6) to a final concentration of 2 μg / ml, and 100 μl / well was added to a 96-well ELISA plate and coated at 37°C for 2 hours. After washing the plate 4 times with 1xPBST, 200 μl / well of PBST solution containing 5% w / v skim milk powder was added thereto and blocked at 37°C for 2 hours. The plate was washed again, and 100 μl / well of gradient diluted antibody (initial concentration was 66.7 nM, 5-fold gradient dilution in PBST containing 2.5% w / v skim milk) was added, and then incubated at 37°C for 40 minutes, and then washed 4 times. Add 1:5000 diluted horseradish peroxidase-labeled affinity-purified Fcγ fragment-specific goat anti-mouse IgG (Jackson ImmunoResearch Laboratories, Inc., Cat#115-035-071) at 100 μl / well and incubate at 37°C for 40 minutes. After the final wash, add 100 μl / well of ELISA color substrate TMB, color at room temperature for 3 to 10 minutes, then stop the color development with 1M sulfuric acid solution, and measure the absorbance of each well at 450-630nm. Use GraphPad Prism software to analyze the data and obtain EC 50 Value, see the result Figure 3 .
[0087] It can be seen from the figure that the A1C8E4H1 monoclonal antibody of the present invention can specifically recognize human SIRPα protein.
[0088] 2.3 Indirect ELISA to determine the cross-reactivity of antibodies with human SIRPβ
[0089] Human SIRPβ-his protein (produced by the company, the plasmid used is SIRPβ-ECD-His; the vector is pCMV-C-His; in the presence of EcoR I and Xba The amino acid sequence inserted between I is MDMRVPAQLLGLLLLWFPGSRCEDELQVIQPEKSVSVAAGESATLRCAMTSLIPVGPIMWFRGAGAGRELIYNQKEGHFPRVTTVSELTKRNNLDFSISISNITPADAGTYYCVKFRKGSPDDVEFKSGAGTELSVRAKPSAPVVSGPAVRATPEHTVSFTCESHGFSPRDITLKWFKNGNEL SDFQTNVDPAGDSVSYSIHSTARVVLTRGDVHSQVICEIAHITLQGDPLRGTANLSEAIRVPPTLEVTQQPMRAENQANVTCQVSNFYPRGLQLTWLENGNVSRTETASTLIENKDGTYNWMSWLLVNTCAHRDDVVLTCQVEHDGQQAVSKSYALEISAHQKEHGSDITHEAALAPTAPLHHHHHHHHHH, SEQ ID NO:25) to a final concentration of 2 μg / ml, add 100 μl / well to a 96-well ELISA plate, and then coat at 37°C for 2 hours. After coating, wash the plate 4 times with 1xPBST, add 200 μl / well PBST solution containing 5% w / v skim milk powder, and place at 37°C for blocking for 2 hours. Wash the plate again, add 100 μl / well gradient diluted antibody or control (starting concentration is 66.7nM, 5-fold gradient dilution in PBST containing 2.5% w / v skim milk) to the plate, incubate at 37°C for 40 minutes, and then wash the plate 4 times. Add 100 μl / well of 1:5000 dilution of horseradish peroxidase-labeled affinity-purified Fcγ fragment-specific goat anti-mouse IgG (Jackson ImmunoResearch Laboratories, Inc., Cat#115-035-071) or horseradish peroxidase-labeled affinity-purified F(ab')2 fragment goat anti-human IgG, Fcγ fragment-specific (Jackson ImmunoResearch Laboratories, Inc., Cat#109-036-098) and incubate at 37°C for 40 minutes. After the final wash, add 100 μl / well of ELISA color substrate TMB, develop at room temperature for 3 to 10 minutes, then stop the color development with 1M sulfuric acid solution, and measure the absorbance of each well at 450-630nm. Use GraphPad Prism software to analyze the data and obtain EC 50Value, the result is Figure 4 .
[0090] As can be seen from the figure, the A1C8E4H1 monoclonal antibody of the present invention can cross-react with the human SIRPβ antigen and has a lower EC 50 The value indicated that its binding activity was better than that of the reference antibody.
[0091] Example 4. Blocking activity detection of mouse anti-SIRPα antibodies
[0092] 4.1 Reference Antibody Blocking ELISA
[0093] The ability of anti-SIRPα antibodies to block the binding of reference antibodies / SIRPα antigens was evaluated by competitive ELISA. Briefly, the reference antibody was prepared with 1xPBS to a final concentration of 2μg / ml, and 100μl / well was added to a 96-well ELISA plate and coated overnight at 4°C. The next day, the plate was washed once with PBST, 200μl / well of PBST solution containing 5% w / v skim milk powder was added, and the plate was blocked at 37°C for 2 hours, and the plate was washed again for 4 times. SIRPα antibody or control was diluted 5-fold in a solution containing biotin-labeled human SIRPα-Fc protein (8.3ng / ml in PBST containing 2.5% w / v skim milk) with a starting concentration of 40nM, and pre-incubated at room temperature for 40 minutes. Then, the incubated antibody and SIRPα-Fc biotin solution were added to the reference antibody-coated plate at 100μl / well, incubated at 37°C for 40 minutes, and the plate was washed again for 4 times. Then, horseradish peroxidase-labeled streptavidin (100 μl / well, 1:10000 diluted in PBST solution containing 5% w / v skim milk powder) was added and incubated at 37°C for 40 minutes. After the final wash, TMB was added for color development, and the reaction was terminated with 1M sulfuric acid, and the absorbance at 450-630 nm was measured. GraphPad Prism software was used for data processing to obtain the IC value of antibody blocking reference antibody / SIRPα binding. 50 Value, the result is Figure 5 .
[0094] As can be seen from the figure, the monoclonal antibody A1C8E4H1 of the present invention can specifically block the binding of SIRPα protein to the reference antibody, indicating that the antibody A1C8E4H1 has the same or similar antigen binding epitope as the reference antibody.
[0095] 4.2 Cell-based ligand blocking FACS
[0096] 293F cells with overexpressed human CD47 protein on the membrane surface (constructed in-house by the company, transfected with lipofectamine3000 transfection reagent to express the full-length human CD47 protein into 293F cells, the vector was pCMV-TP, and the expression of human CD47 protein was detected by EcoR The sequence inserted by I and XbaI is MWPLVAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELKYRVVSWFSPNENILIVIFPIFAILLFWGQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAILFVPGEYSLKNATGLGLIVTSTGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACIPMHGPLLISGLSILALAQLLGLVYMKFVASNQKTIQPPRNN, SEQ ID NO: 26). The ability of anti-SIRPα antibody to block the binding of SIRPα protein to CD47 protein on the cell membrane surface was determined by flow cytometry (FACS).
[0097] SIRPα antibody or control with a starting concentration of 66.67nM was diluted 5-fold in a biotinylated human SIRPα-Fc protein solution and pre-incubated at room temperature for 40 minutes. CD47-293F cells in the logarithmic growth phase were collected from the cell culture flask, washed twice with PBS, and resuspended in FACS buffer (PBS solution containing 2% fetal bovine serum). The cell density was adjusted to 1x10 5100 cells / well were plated in a 96-well U-bottom plate, centrifuged at 300g for 5 minutes, and the supernatant was discarded. Then, the incubated antibody and human SIRPα-Fc biotin solution was added to the cell plate containing CD47-293F cells at 100μl / well. After incubation at 4℃ for 40 minutes, centrifuged at 300g for 5 minutes, and the supernatant was discarded. The cells were washed twice with FACS buffer, and 100μL / well R phycoerythrin streptavidin (Jackson Immunoresearch, Cat#016-110-084, diluted 1:500 in FACS buffer) was added. After incubation at 4℃ for 40 minutes, centrifuged at 300g for 5 minutes, and the supernatant was discarded. The cells were washed twice with FACS buffer. Then, 100μL of FACS buffer was added to each well to resuspend, and the cells were blown evenly before detection on the machine. The mean fluorescence intensity (MFI) value of each well was measured using a Becton Dickinson FACSCanto II-HTS flow cytometer. GraphPad Prism software was used for data processing to obtain the IC value of antibody binding to cells. 50 Concentration value, the result is as follows Figure 6 .
[0098] As can be seen from the figure, the A1C8E4H1 monoclonal antibody of the present invention can specifically block the binding of human SIRPα protein to human CD47 ligand on the cell membrane surface, and its blocking ability is better than that of the reference antibody, indicating that the A1C8E4H1 of the present invention is a functional antibody with SIRPα / CD47 blocking activity that is superior to the reference antibody.
[0099] Example 5 DNA cloning and sequencing, variable region sequencing of anti-SIRPα mouse monoclonal antibody
[0100] Total RNA was extracted from cultured mouse monoclonal cell lines using FastPure Cell / Tissue Total RNA Isolation Kit (Vazyme, Cat#RC101). The process is briefly described as follows: 1.5x10 6Transfer the treated cells to a 1.5ml centrifuge tube and aspirate the supernatant. Add 500μl Buffer RL1 to the cell pellet and mix by pipetting. Transfer the treated cells to gDNA-Filter Columns (gDNA-Filter Columns have been placed in the collection tube), centrifuge at 13,000g for 2 minutes at room temperature, and retain the supernatant in the collection tube. Add 1.6 times the volume of Buffer RL2 and mix gently. Transfer the mixture to RNAPure Columns, centrifuge at 13,000g for 1 minute at room temperature, and discard the waste liquid. Add 500μl Buffer RW1 to RNAPure Columns, centrifuge at 13,000g for 1 minute at room temperature, and discard the waste liquid. Add 700μl Buffer RW2, centrifuge at 13,000g for 1 minute at room temperature, and discard the waste liquid. Add another 700μl Buffer RW2, centrifuge at 13,000g for 1 minute at room temperature, and discard the waste liquid. Centrifuge at 13,000g for 2 minutes to completely remove the residual Buffer RW2 in the RNAPure Columns. Transfer the adsorption column to a new RNase-free CollectionTubes 1.5ml centrifuge tube, and add 50μl of RNase-free ddH2O to the center of the adsorption column. Leave at room temperature for 2 minutes, and centrifuge at 13,000g for 1 minute to elute the RNA.
[0101] Next, Takara's reverse transcription cDNA kit (Cat#6210A) was used to convert total RNA into cDNA. The experimental system was prepared as follows: 5μl total RNA + 0.5μl Oligo (dT) Primer + 0.5μl Random 6mers + 1.0μl dNTPMixture + 3.0μl RNase-free ddH2O (a total of 10μl). First, place it at 65℃ for 5min for pre-denaturation, and then put it on ice for 2min. Further add 4μl 5x PrimeScript II Buffer + 0.5μl RNase Inhibitor + 1.0μl PrimeScriptII RTase + 4.5μl RNase-free ddH2O (a total of 20μl system), mix well after preparation, use a PCR instrument to run at 40℃ for 50min, then turn to 70℃ for 10min to complete cDNA synthesis.
[0102] The cDNA was further added with Poly G at the 3' end. The reaction system was prepared as follows: 5μl cDNA + 33.5μl ddH2O + 5μl 10x TdT Buffer + 5μl CoCl + 1μl dGTP + 0.5μl Terminal TransPerase (a total of 50μl system). After preparation, mix well and run the PCR instrument at 37℃ for 30min, then transfer to 70℃ for 10min to complete Poly G tailing.
[0103] Further, the tailed cDNA was used as a template for gene amplification of the antibody variable region. For amplification of the antibody heavy chain variable region sequence, a kit from Novagen (Cat#P525-03) was used to prepare the PCR reaction system: 25 μl 2x Phanta MaxMaster Mix (Dye Plus) + 2.0 μl BSJ-Pri3 AntisenseP-mIgG1 (nucleotide sequence is GCATCCCAGGGTCACCATGGAGTTAGTT, SEQ ID NO: 27) + 2.0 μl BSJ-Pri1 Universal C1 (nucleotide sequence is
[0104] AAGCAGTGGTATCAACGCAGAGTCATCCCCCCCCCCCCCCCC, SEQ ID NO: 28) + 1.25 μl cDNA with PolyG tail + 19.75 μl ddH2O (50 μl system in total). For amplification of antibody light chain variable region sequence, first use Takara's kit (Cat#R010A) to prepare the PCR reaction system: 10 μl 5x PrimeSTAR Buffer + 0.5 μl PrimeSTAR + 1.25 μl BSJ-Pri1Universal C1 (nucleotide sequence is AAGCAGTGGTATCAACGCAGAGTCATCCCCCCCCCCCCCCCC, SEQ ID NO: 28) + 1.25 μl BSJ-Pri19 (nucleotide sequence is GCAACCGACTGAGGCACCTCCAGATGTT, SEQ ID NO: 29) + 4 μl aberrant-L-R2 (nucleotide sequence is
[0105] TCTGGCTATAGTTATATGCACTGGAACCAACAGAAACCAGGACAGC, SEQ ID NO: 30) + 4 μl dNTP + 1.25 μl cDNA with Poly G tail + 27.75 μl ddH2O (a total of 50 μl system).
[0106] The temperature cycle for PCR amplification of the antibody heavy chain variable region is as follows:
[0107] 98℃*5min+(98℃*10s+62℃*10s+72℃*1min)*2Cycle+
[0108] (98℃*10s+60℃*10s+72℃*1min)*4Cycles+
[0109] (98℃*10s+58℃*10s+72℃*1min)*10Cycles+
[0110] (98℃*10s+56℃*10s+72℃*1min)*20Cycles+
[0111] 72℃*10min+4℃*∞
[0112] The temperature cycle for PCR amplification of the antibody light chain variable region is as follows:
[0113] 98℃*5min+(98℃*10s+64℃*10s+72℃*1min)*2Cycle+
[0114] (98℃*10s+62℃*10s+72℃*1min)*6Cycles+
[0115] (98℃*10s+60℃*10s+72℃*1min)*12Cycles+
[0116] (98℃*10s+58℃*10s+72℃*1min)*16Cycles+
[0117] 72℃*10min+4℃*∞
[0118] The PCR product was analyzed by 1% agarose gel electrophoresis, and the DNA segment bands of corresponding sizes (about 500 bp for VH and about 500 bp for Vkappa light chain) were cut out and DNA was extracted using TIANGEN's gel DNA recovery kit (Cat# DP209-03). The brief description is as follows: the gel was weighed, an equal volume of solution PN was added, and then incubated at 50 degrees Celsius for 10 minutes until the gel was completely dissolved. The resulting solution was transferred to the CA2 adsorption column (the adsorption column was placed in the collection tube), left at room temperature for at least 2 minutes, centrifuged at 12,000 rpm at room temperature for 30 seconds, and the waste liquid was discarded. 600 μl of rinsing solution PW was added to the column, and then centrifuged at 12,000 rpm at room temperature for 30 seconds, and the waste liquid was discarded. 600 μl of rinsing solution PW was added to the column again, left to stand for 5 minutes, centrifuged at 12,000 rpm at room temperature for 30 seconds, and the waste liquid was discarded. Centrifuge again at 12,000 rpm for 2 minutes at room temperature to remove the residual liquid in the column, and leave it at room temperature for at least 2 minutes to completely dry the residual liquid. Place the adsorption column in a clean centrifuge tube, add 35 μl of elution buffer EB, and leave it at room temperature for at least 2 minutes. Centrifuge at 12,000 rpm for 2 minutes to obtain the prepared DNA sample. The purified PCR product is sequenced to obtain the variable region sequence of the antibody.
[0119] The sequence information of the clones of the present invention is shown in Tables 2 to 4.
[0120] Table 2 Sequence information of anti-SIRPα antibodies
[0121]
[0122] NA: nucleotide; AA: amino acid.
[0123] Table 3. Amino acid sequences of anti-SIRPα antibodies
[0124]
[0125]
[0126] Table 4. Nucleotide sequences of anti-SIRPα antibodies
[0127]
[0128]
[0129]
[0130] Heavy chain amino acid sequence of KWAR23:
[0131] EVQLQQSGAELVKPGASVKLSCTASGFNIKDYYIHWVQQRTEQGLEWIGRIDPEDGETKYAPKFQD
[0132] KATITADTSSNTAYLHLSSLTSEDTAVYYCARWGAYWGQGTLVTVSAASTKGPSVFPLAPCSRSTSES
[0133] TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHK
[0134] PSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN
[0135] WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKG
[0136] QPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:21)
[0137] Amino acid sequence of the light chain of KWAR23:
[0138] QIVLTQSPAIMSASPGEKVTLTCSASSSVSSSYLYWYQQKPGSSPKLWIYSTSNLASGVPARFSGSGSG
[0139] TSYSLTISSMEAEDAASYFCHQWSSYPRTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLL
[0140] NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:22)
[0141] In summary, the monoclonal antibody A1C8E4H1 of the present invention can specifically recognize human SIRPα with high affinity, and has cross-reactivity with cynomolgus monkey SIRPα. In addition, it can specifically block the binding between human SIRPα and human CD47. It has a novel sequence and is a new anti-SIRPα monoclonal antibody.
[0142] Although the content of the present invention has been described in detail through the above preferred embodiments, it should be appreciated that the above description should not be considered as a limitation of the present invention. After reading the above content, it will be apparent to those skilled in the art that various modifications and substitutions of the present invention will occur. Therefore, the protection scope of the present invention should be limited by the appended claims.
Claims
1. A monoclonal antibody that specifically binds to human SIRPα, characterized in that: The monoclonal antibody comprises a heavy chain variable region and a light chain variable region; The heavy chain variable region comprises CDR-H1, CDR-H2 and CDR-H3, and the light chain variable region comprises CDR-L1, CDR-L2 and CDR-L3; The amino acid sequence of the CDR-H1 is shown in SEQ ID NO: 2; The amino acid sequence of the CDR-H2 is shown in SEQ ID NO: 4; The amino acid sequence of the CDR-H3 is shown in SEQ ID NO: 6; The amino acid sequence of the CDR-L1 is shown in SEQ ID NO: 12; The amino acid sequence of the CDR-L2 is shown in SEQ ID NO: 14; The amino acid sequence of the CDR-L3 is shown in SEQ ID NO:
16.
2. The monoclonal antibody that specifically binds to human SIRPα according to claim 1, characterized in that: The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:8; the amino acid sequence of the light chain variable region is shown in SEQ ID NO:
18.
3. The monoclonal antibody that specifically binds to human SIRPα according to claim 1, characterized in that: The heavy chain amino acid sequence is shown in SEQ ID NO: 10; the light chain amino acid sequence is shown in SEQ ID NO:
20.
4. A nucleotide molecule, characterized in that The nucleotide molecule encodes the monoclonal antibody that specifically binds to human SIRPα according to any one of claims 1 to 3.
5. The nucleotide molecule according to claim 4, characterized in that The sequence of the nucleotide molecule is selected from SEQ ID NO: 7 and SEQ ID NO: 17; The sequence SEQ ID NO: 7 encodes the heavy chain variable region of the monoclonal antibody; The sequence SEQ ID NO: 17 encodes the light chain variable region of the monoclonal antibody.
6. An expression vector, characterized in that: The expression vector contains the nucleotide molecule as described in claim 4 or 5.
7. A host cell, characterized in that The host cell contains the expression vector according to claim 6.
8. The method for preparing a monoclonal antibody that specifically binds to human SIRPα according to any one of claims 1 to 3, characterized in that: The following steps are included: Preparing an expression vector containing a nucleotide molecule for expressing a monoclonal antibody that specifically binds to human SIRPα as described in any one of claims 1 to 3; The obtained expression vector is transfected into eukaryotic host cells and cultured; The antibody is obtained by separation and purification. 9 . An antibody immunoconjugate, a bispecific molecule, a chimeric antigen receptor or a pharmaceutical composition comprising the monoclonal antibody that specifically binds to human SIRPα according to any one of claims 1 to 3 .
10. Use of the monoclonal antibody specifically binding to human SIRPα according to any one of claims 1 to 3 in the preparation of anti-tumor drugs.
